Altered SDF-1/CXCR4 axis in patients with primary myelofibrosis and in the Gata1 low mouse model of the disease.

Experimental Hematology
Anna Rita MigliaccioRonald Hoffman

Abstract

To assess whether alterations in the stromal cell-derived factor-1 (SDF-1)/CXCR4 occur in patients with primary myelofibrosis (PMF) and in Gata1 low mice, an animal model for myelofibrosis, and whether these abnormalities might account for increased stem/progenitor cell trafficking. In the mouse, SDF-1 mRNA levels were assayed in liver, spleen, and marrow. SDF-1 protein levels were quantified in plasma and marrow and CXCR4 mRNA and protein levels were evaluated on stem/progenitor cells and megakaryocytes purified from the marrow. SDF-1 protein levels were also evaluated in plasma and in marrow biopsy specimens obtained from normal donors and PMF patients. In Gata1 low mice, the plasma SDF-1 protein was five times higher than normal in younger animals. Furthermore, SDF-1 immunostaining of marrow sections progressively increased with age. Similar abnormalities were observed in PMF patients. In fact, plasma SDF-1 levels in PMF patients were significantly higher (by twofold) than normal (p < 0.01) and SDF-1 immunostaining of marrow biopsy specimens demonstrated increased SDF-1 deposition in specific areas. In two of the patients, SDF-1 deposition was normalized by curative therapy with allogenic stem cell transplantation. Similar t...Continue Reading

References

Jun 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·M van de RijnI L Weissman
Jun 24, 1997·Proceedings of the National Academy of Sciences of the United States of America·M A McDevittS H Orkin
Feb 25, 1998·Stem Cells·R S Taichman, S G Emerson
May 13, 1999·Proceedings of the National Academy of Sciences of the United States of America·K KawabataT Nagasawa
Sep 9, 2000·The New England Journal of Medicine·J Benbassat
Dec 6, 2000·The Journal of Clinical Investigation·T PonomaryovT Lapidot
Sep 26, 2001·The Journal of Biological Chemistry·G A McQuibbanC M Overall
Feb 28, 2002·The Journal of Biological Chemistry·Agustín Valenzuela-FernándezFernando Arenzana-Seisdedos
Jun 19, 2002·The Journal of Clinical Investigation·Thanyaphong Na NakornKoichi Akashi
Aug 1, 2002·Blood·Alessandro Maria VannucchiAnna Rita Migliaccio
Apr 12, 2003·Current Opinion in Hematology·Thalia Papayannopoulou
Oct 24, 2003·Nature·L M CalviD T Scadden
Apr 20, 2005·The Journal of Experimental Medicine·Hal E BroxmeyerEdward F Srour
May 19, 2005·American Journal of Clinical Pathology·Hongyu NiRonald Hoffman
Mar 14, 2007·Blood Cells, Molecules & Diseases·Vittorio RostiUNKNOWN Myeloproliferative Disorders Research Consortium

❮ Previous
Next ❯

Citations

Oct 23, 2013·Current Hematologic Malignancy Reports·Niccolò BartalucciAlessandro M Vannucchi
Sep 5, 2008·Leukemia·J KotaS N Constantinescu
Mar 6, 2012·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Sonam PrakashAttilio Orazi
Mar 31, 2011·Nature Reviews. Clinical Oncology·Claudio TripodoStefano A Pileri
Jan 21, 2010·Current Opinion in Hematology·Andrew T Chen, Josef T Prchal
Sep 10, 2008·Blood·Ross L Levine, D Gary Gilliland
Sep 23, 2014·Bone·Mara RiminucciPaolo Bianco
Oct 2, 2014·Nature Communications·Silvia BatistaKairbaan Hodivala-Dilke
Nov 26, 2008·Stem Cells and Development·Barbara GhinassiAnna Rita Migliaccio
Oct 3, 2018·Leukemia & Lymphoma·Sonia Emilia SeliceanIoana Berindan-Neagoe
Dec 13, 2018·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·A NoninoR H Jacomo
May 31, 2008·Stem Cells·Costanza BoganiUNKNOWN Myeloproliferative Disorders Research Consortium
Jan 30, 2010·Journal of Cellular Physiology·Barbara GhinassiAnna Rita Migliaccio
May 12, 2010·Journal of Cellular Physiology·Maria VerrucciAnna Rita Migliaccio
Nov 5, 2011·FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology·Gregor HoermannMatthias Mayerhofer
Nov 22, 2019·IUBMB Life·Maria ZingarielloAnna Rita Migliaccio
Jul 22, 2016·Oncotarget·Hadjer AbdelouahabFawzia Louache
May 18, 2020·Annals of Hematology·Douglas TremblayJohn Mascarenhas
Aug 29, 2014·Hepatology Research : the Official Journal of the Japan Society of Hepatology·Yedidya SaimanMeena B Bansal
Mar 23, 2018·International Journal of Molecular Sciences·Moo-Kon SongJi-Eun Uhm
Apr 15, 2010·Cancer Research·Sool Yeon ChoRonald Hoffman
Oct 6, 2020·Seminars in Diagnostic Pathology·Sonam PrakashWayne Tam

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.